1 citations
,
September 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” γδ T cells are crucial for early wound healing after a skin virus infection.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Targeting specific T cells may help treat alopecia areata.
1 citations
,
August 2016 in “Journal of Investigative Dermatology” Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.
3 citations
,
March 2024 in “Viruses” γδ T cells are essential for wound healing after poxvirus infection.
7 citations
,
February 2015 in “Journal of comparative pathology” CD8+ T cells play a key role in graft-versus-host disease in certain mice models.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
23 citations
,
September 2020 in “Journal of Dermatological Science” Targeting Vδ1+T-cells may help treat alopecia areata.
November 2025 in “The Journal of Immunology” Different γδ T cell types have unique roles in causing alopecia areata.
14 citations
,
January 2016 in “Experimental and molecular pathology” Giving immune serum from vaccinated mice to mice without T cells prevents infection and tumor growth.
July 2023 in “Nature Immunology” CD8+ virtual memory T cells may cause hair loss in alopecia areata.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” The study suggests a link between varicella-zoster virus and segmental vitiligo, with evidence of the virus disrupting skin pigment cells.
April 2018 in “Journal of Investigative Dermatology” The role of γδT-cells in causing alopecia areata remains unclear.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
1 citations
,
April 2017 in “Journal of Dermatological Science” Certain immune cells may cause hair loss by reacting to stressed hair follicles.
CMV infection increases the risk of GvHD after bone marrow transplants.
September 2024 in “Journal of the American Academy of Dermatology” Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.
July 2025 in “Journal of Investigative Dermatology” γδ T cells can prevent and treat alopecia areata, offering a new therapy option.
23 citations
,
January 2024 in “Nature Immunology” γδ T cells adapt uniquely to different tissues in mice.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
December 2023 in “Journal of Investigative Dermatology” A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
24 citations
,
October 2022 in “Cell Regeneration” A new mouse model effectively mimics vitiligo for research and drug testing.
1 citations
,
May 2023 in “The Journal of Immunology” CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.
155 citations
,
May 2016 in “Nature communications” Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.
47 citations
,
June 2013 in “Biology of blood and marrow transplantation” Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.
35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.
January 2026 in “Pediatrics International” Live vaccines can be safely given to infants with a FOXN1 variant if their immune function improves over time.